.jpg)
The Nasdaq Stock Market, Inc. (Nasdaq:NDAQ) and NeuroInsights, LLC announced today the launch of the NASDAQ(r) NeuroInsights(r) Neurotech Index, an innovative and powerful tool for investing in technologies that are changing the medical landscape of brain and nervous system disorders. NeuroInsights is the world's leading neurotechnology research and advisory firm, helping investors, industry executives and the public understand trends and developments in the neurotechnology sector. NASDAQ began disseminating the index today.
The NASDAQ NeuroInsights Neurotech Index is designed to track the performance of the leading neurotechnology companies which are listed and actively traded on one of the three major U.S. stock exchanges. The NASDAQ NeuroInsights Neurotech Index includes companies engaged in researching, developing, manufacturing and marketing pharmaceuticals, biologics, medical devices and diagnostics for the brain and nervous system.
"Driven by recent advancements in computing technology and basic brain research, neurotechnology is one of the fastest growing industries in the world," said NASDAQ Executive Vice President John Jacobs. "As the leading index provider, NASDAQ has fulfilled an important need by collaborating with NeuroInsights to develop a benchmark that enables investors to track this rapidly growing sector. This index underscores NASDAQ's commitment to provide access to the most forward-thinking and innovative investment opportunities available."
"Neurotechnology has become a $120 billion global industry, bringing new and exciting public and private investing opportunities," said Casey Lynch, Managing Director of NeuroInsights. "Working with NASDAQ to create this index illuminates the promise of the brain industry and reflects the incredible progress being made in the battle against illnesses such as Alzheimer's, addiction, anxiety, depression, epilepsy, obesity, pain, Parkinson's, schizophrenia, sensory disorders, sleep disorders, stroke, and traumatic brain injury."
The NASDAQ NeuroInsights Neurotech Index is calculated using a modified market capitalization-weighted methodology. The index will be calculated on a price return basis (Nasdaq:NERV). Companies included in the index must be listed on The NASDAQ Stock Market, the New York Stock Exchange, or the American Stock Exchange and be identified by NeuroInsights as significantly involved in the neurotechnology industry.
NASDAQ Financial Products (NFP) is engaged in the design, development, calculation, licensing, and marketing of NASDAQ indexes. NFP specializes in the development of indexes focusing on NASDAQ's brand themes of innovation, technology, growth, and globalization. More than 500 financial products sold in 36 countries are based on NASDAQ indexes. NFP also provides custom index services and design solutions as a third-party provider to selected financial organizations.
About NeuroInsights
NeuroInsights is the world's leading neurotechnology research and advisory firm. As the neurotechnology market authority, NeuroInsights helps investors, industry and society understand and profit from the rapid growth in drugs, devices and diagnostics for the brain and nervous system. NeuroInsights provides market reports, investment information, industry events and strategic advisory services to venture funds, startups, corporations, governments and financial institutions. For more information, visit www.neuroinsights.com.
About NASDAQ
NASDAQ is the largest U.S. equities exchange. With approximately 3,200 companies, it lists more companies and, on average, trades more shares per day than any other U.S. market. It is home to companies that are leaders across all areas of business including technology, retail, communications, financial services, transportation, media and biotechnology. NASDAQ is the primary market for trading NASDAQ-listed stocks as well as a leading liquidity pool for trading NYSE-listed stocks. For more information about NASDAQ, visit the NASDAQ Web site at www.nasdaq.com or the NASDAQ Newsroom at www.nasdaq.com/newsroom/.
